Clinical Trials Logo

Clinical Trial Summary

Overuse is common in frail older people with polypharmacy, especially in frail older users of multidose drug dispensing (MDD) systems. In this study, we will investigate the effect of a clinical medication review (CMR) with integration of deprescribing (toolbox) on the number of ceased and dose lowered medications (persistent after 6 months) compared to usual care in older users of MDD systems with hyperpolypharmacy. We will perform a controlled cluster-randomized trial in 38 community pharmacies. Per pharmacy, 10 older patients (>= 75) with hyperpolyfpharmacy (>10 medicines in use) with a MDD will be included. Pharmacists will receive training to perform the intervention, a 5-step CMR with a deprescribing toolbox (including deprescribing protocols): 1) patient interview; 2) pharmacotherapeutic analysis; 3) pharmacist and GP discuss actions; 4) actions are discussed with patient; 5) (two)weekly follow-up.


Clinical Trial Description

AIM: is to investigate the effect of a clinical medication review in combination with a toolbox about deprescribing. STUDY DESIGN: a controlled cluster-randomized trial will be performed, in which participating pharmacists in the Netherlands will be randomized to conduct clinical medication reviews with 10 eligible patients (intervention) or to provide usual care (control). STUDY POPULATION: hyperpolypharmacy (≥ 10 chronic drugs) older patients (≥75 years) using a multidose drug dispensing (MDD) system INTERVENTION: the intervention at t=0 consists of a 5-step patient-centred CMR focuses on deprescribing supported by the toolbox developed in WP1. The CMR starts with a patient interview (step 1) by a community pharmacist focussing on patient's preferences with input from the questionnaires on healthproblems, frailty and patient wishes. After the pharmacotherapeutic analysis (step 2), the pharmacist and the GP discuss the identified patient preferences and possible actions, including deprescribing (step 3). When patients are treated for one of more disease by a hospital specialist, pharmacist or GP consults this physician when appropriate. The health care providers decide together with the patient which actions will be conducted and their priority. This will result in a pharmaceutical care plan taking into account the tapering schemes from the deprescribing protocols (step 4). All actions and deprescribing steps will be evaluated with the patient during at least two follow-up moments (or more according to the patient's needs) to monitor the results of the actions. The follow-up moments can be performed by nurse practitioners or GPs with consultation of the community pharmacist when needed, e.g. to adapt tapering schemes based on the patient's health problems or withdrawal symptoms (step 5). CONTROL: usual care. OUTCOME MEASURES: the primary outcome measure is the number of ceased or dose lowered drugs per patient persistent after 6 months. Secondary, PREMs and PROMs including quality of life will be measured, as well as intermediate outcomes and process related outcomes DATA-ANALYSIS: Intention-to-treat analysis and a per-protocol-analysis for the primary outcome and PROM, and an explorative subgroup analysis (age, gender, health problems, number of medicines in use). Descriptive analysis of other outcomes (intervention group only). SAMPLE SIZE: To detect an effect size of 1 ceased / dose lowered drug (standard deviation 2.5), 80% power and α=0.05, we need a total of 266 patients for the analysis of the primary outcome and to account for clustering effects within pharmacies (ICC = 0,05 and clustersize = 7). Taking loss to follow-up into account (35%), 38 teams need to recruit 10 patients each. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05609981
Study type Interventional
Source SIR Institute for Pharmacy Practice and Policy
Contact Gert Baas, MSc
Phone +31 71 5766157
Email g.w.baas@sirstevenshof.nl
Status Recruiting
Phase N/A
Start date November 10, 2022
Completion date November 2023

See also
  Status Clinical Trial Phase
Completed NCT03688542 - Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module N/A
Completed NCT02545257 - Development of a Coordinated, Community-Based Medication Management Model for Home-Dwelling Aged in Primary Care N/A
Withdrawn NCT01932632 - Medication Minimization for Long-term Care Residents N/A
Recruiting NCT04615065 - Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Active, not recruiting NCT04181879 - Appropriate Polypharmacy in Older People in Primary Care N/A
Not yet recruiting NCT03283735 - Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal N/A
Completed NCT02918058 - Reducing Post-discharge Potentially Inappropriate Medications Among Older Adults N/A
Enrolling by invitation NCT05656560 - Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges R01 Trial N/A
Completed NCT03655405 - Randomised, Controlled Trial of an Individual Deprescribing Intervention for Nursing Homes Residents N/A
Completed NCT04575155 - Development & Pilot of the Technology-Enabled Alliance for Medication Therapy Management N/A
Withdrawn NCT05816967 - Rationalisation of Polypharmacy by the RASP-instrument and Discharge Counselling of Geriatric Inpatients N/A
Completed NCT05616689 - Bundled Hyperpolypharmacy Deprescribing N/A
Terminated NCT04055896 - Team Approach to Polypharmacy Evaluation and Reduction in a Long-Term Care Setting N/A
Active, not recruiting NCT03052192 - Biological Aging, Medication, Malnutrition and Inflammation Among Acutely Ill and Healthy Elderly.
Completed NCT02866799 - Multi-PAP: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy N/A
Completed NCT01732302 - Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients N/A
Enrolling by invitation NCT05053815 - Pharmacogenomic Testing in a Program of All-inclusive Care for the Elderly (PACE) Setting
Recruiting NCT04585191 - Reducing Treatment Risk in Older Adults With Diabetes N/A
Active, not recruiting NCT04120480 - Effectiveness of PGx Testing N/A
Recruiting NCT05501223 - Physician-initiated Medication Review in a Type 2 Diabetes Outpatient Clinic N/A